Moreno Nogueira J A, Ruiz Borrego M, Pérez Valderrama B, Valero Azbiru M
Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla, España.
Rev Clin Esp. 2009 Feb;209(2):88-92. doi: 10.1016/s0014-2565(09)70632-0.
Aggressive non-Hodgkin's lymphomas (NHL) in localized stages I and II, without bulky areas and a fair International Prognostic Factor (IPI) (30% of all cases) have high possibilities of cure (80%) when treated with combined chemotherapy, CHOP or CHOP-like (3-4 courses) followed by locoregional radiation therapy. Localized aggressive non-Hodgkin's lymphomas with signs of poor prognosis or advanced stages (III and IV) must be treated with rituximab-containing immunochemotherapy. As second line in responding patients (DHAP, ESHAP, MINE, VIM, DICE, etc., and rituximab) high doses chemotherapy with hematopoietic growth factor support should be considered, although not in refractory patients.
局限性I期和II期的侵袭性非霍奇金淋巴瘤（NHL），无大包块区域且国际预后指数（IPI）良好（占所有病例的30%），采用联合化疗、CHOP或类似CHOP方案（3 - 4个疗程）并序贯局部区域放射治疗时，治愈可能性很高（80%）。伴有预后不良征象或晚期（III期和IV期）的局限性侵袭性非霍奇金淋巴瘤必须采用含利妥昔单抗的免疫化疗进行治疗。对于缓解期患者（DHAP、ESHAP、MINE、VIM、DICE等方案以及利妥昔单抗），作为二线治疗，应考虑给予造血生长因子支持下的大剂量化疗，但难治性患者除外。
